


-60-

ABSTRACT

PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES

5

The present invention concerns the compounds of formula



- the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
- 10 $a^1-a^2=a^3-a^4$ represents a divalent radical selected from N-CH=CH-CH, N-CH=N-CH or CH-CH=N-CH;
- Z represents NH; Y represents -C₃₋₉alkyl-, -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₆alkyl-NH-CO- or -CO-NH -C₁₋₆alkyl- ;
- 15 X¹ represents -O- or -NR¹¹-; X² represents -C₁₋₂alkyl-, -O-C₁₋₂alkyl-, -O- or -O-CH₂-; R¹ represents hydrogen or halo;
- R² represents hydrogen, cyano, halo, hydroxycarbonyl-, C₁₋₄alkyloxycarbonyl-, Het¹⁶-carbonyl- or Ar⁵; R³ represents hydrogen;
- R⁴ represents hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents C₁₋₄alkyloxy
- 20 substituted with one or where possible two or more substituents selected from C₁₋₄alkyloxy- or Het²-;
- R¹¹ represents hydrogen;
- R¹² represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;
- R¹³ represents Het¹⁴-C₁₋₄alkyl, in particular morpholinyl-C₁₋₄alkyl;
- 25 Het² represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl;
- Het¹⁴ represents morpholinyl;
- Het¹⁶ represents a heterocycle selected from morpholinyl or pyrrolidinyl;
- Ar⁴ represents phenyl; Ar⁵ represents phenyl optionally substituted with cyano.